This story was first published in digitalhealth.net
Roflumilast approved by NICE for routine NHS use
NICE has approved a treatment called roflumilast, also known as Daxas, to treat chronic obstructive pulmonary disease (COPD).
When the treatment was first reviewed by NICE in 2012, limited data meant that it was recommended only if patients were using it as part of a clinical trial. After two new trials showed the drug helped ease symptoms that were not being controlled with inhalers, NICE reviewed and approved it for eligible patients.
It is recommended as an option to treat adults with severe COPD whose symptoms continue to worsen despite other treatments. It is a once-a-day tablet that works to reduce irritation and swelling in airways of people with the condition.
Around 122,000 adults in England will be eligible to receive roflumilast.
Professor Carole Longson, director of the NICE centre for health technology evaluation, said: “COPD is a chronic lung condition which causes breathing problems and for many, symptoms will only worsen with time. New evidence has meant we can now say that roflumilast should be routinely available to patients with severe COPD. This will be welcome news for many patients who have severe COPD symptoms that have been difficult to control.”
Latest News
16/02/2024 - 12:56
Hammersmith and Fulham Council has created a new alliance intended to clean dirty air and improve residents' health.
16/02/2024 - 10:44
Two million more GP appointments a month are being delivered for patients compared to the same month before the pandemic as part of the NHS primary care access recovery plan according to new NHS data.
15/02/2024 - 10:26
The Welsh Government has provided innovation funding of £380,000 to support two projects utilising technology in domiciliary care.
15/02/2024 - 10:13
The new Scottish health secretary has met with frontline staff at Queen Elizabeth University Hospital in Glasgow.
14/02/2024 - 10:27
The North East London NHS Foundation Trust (NELFT) has appointed three new Executive Directors to the Trust Board.
Product Features
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Supplier Profiles
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Latest Features
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly
